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Aims and objectives: With the relentless increase in multidrug- and extensively-drug resis-
tant tuberculosis (MDR/XDR-TB), new treatment strategies are necessary. Favorable results
have been reported by combining a b-lactam antibiotic and a b-lactamase inhibitor. The
b-lactamase encoded by the blaC gene of Mycobacterium tuberculosis (MTB) is the major
mechanism of resistance to b-lactam antibiotics (e.g., penicillin). Meropenem, a b-lactam
antibiotic of the carbapenem group, is a relatively weak substrate for the b-lactamase of
MTB. The b-lactamase inhibitor clavulanate irreversibly inactivates the b-lactamase
encoded by the blaC gene, thus making the combination of meropenem and clavulanate
an interesting treatment alternative for MTB. However, very few isolates of MTB have been
tested for this drug combination and few clinical reports exist. Thus, the present study
investigates the in vitro activity of meropenem-clavulanate for drug-resistant MTB isolates,
including MDR/XDR-TB.
Methods: The minimum inhibitory concentration (MIC) distribution of meropenem-clavul-
anate was determined using Middlebrook 7H10, including MDR and XDR strains of MTB
(n = 68). Meropenem was prepared in a stock solution with a final concentration range of
0.002–512 mg/L. Clavulanate was added at a fixed concentration of 64 mg/L, to avoid a
decline of the b-lactamase to insufficient levels during the experiment. All isolates were
evaluated after three weeks of growth. The pan-susceptible strain H37Rv was used as a
control.
Results: There was a Gaussian MIC-distribution between 0.125 and 2 mg/L of meropenem-
clavulanate (expressed as the concentration of meropenem), but four isolates had very high
MIC levels (16 and 32 mg/L), which is likely to be out of reach in clinical doses (Fig. 1). The
susceptibility of the isolates to meropenem-clavulanate was not correlated to the level of
resistance to first- or second-line anti-tuberculous drugs. The MIC of the pan-susceptible, Sweden.
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Fig. 1 – The MIC-distribution of meropen
the M. tuberculosis isolates (n = 68) tested
7H10 medium, as follows: non-MDR/XDR
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shows the concentration of meropenem,
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Conclusions: The present study shows that meropenem-clavulanate has low MICs against
MTB in vitro, including MDR and XDR-TB isolates. Meropenem has good tissue penetration
and low protein-binding, but requires an intravenous access and is relatively expensive.
Meropenem-clavulanate may be a treatment option in selected cases of MDR/XDR-TB,
although further clinical studies are warranted.
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